LENALIDOMIDE
Manner of administration:Oral
Restriction
Indication: Multiple myeloma
Treatment phase: Initial treatment with triple therapy (this drug, bortezomib and dexamethasone) for
the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle
Restriction
Indication: Multiple myeloma
Treatment phase: Continuing treatment of triple therapy (this drug, bortezomib and dexamethasone) for
treatment cycles 5 to 8 inclusive (administered using 21-day treatment cycles)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 14 | # of repeats: 3 | DPMQ: $534.25 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenalide | |||||
Manner of administration:Oral
Restriction
Indication: Multiple myeloma
Treatment phase: Initial treatment with triple therapy (this drug, bortezomib and dexamethasone) for
the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle
Restriction
Indication: Multiple myeloma
Treatment phase: Continuing treatment of triple therapy (this drug, bortezomib and dexamethasone) for
treatment cycles 5 to 8 inclusive (administered using 21-day treatment cycles)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 14 | # of repeats: 3 | DPMQ: $505.16 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenalide | |||||